HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B.

Abstract
Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis. Optimal dose is not defined. We described a case of pulmonary mucormycosis, which had been treated with 42.55 g (during to 45 weeks) liposomal amphotericin B. In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.
AuthorsFatih Erbey, Emine Kocabaş, İbrahim Bayram, Süreyya Soyupak, Derya Gümürdülü, Atila Tanyeli
JournalTuberkuloz ve toraks (Tuberk Toraks) Vol. 60 Issue 4 Pg. 375-9 ( 2012) ISSN: 0494-1373 [Print] Turkey
PMID23289469 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antifungal Agents
  • Amphotericin B
Topics
  • Amphotericin B (administration & dosage, therapeutic use)
  • Antifungal Agents (administration & dosage, therapeutic use)
  • Child
  • Dose-Response Relationship, Drug
  • Humans
  • Male
  • Mucormycosis (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: